Biotech Company Secures $453 Million Award For Covid-19 Oral Pill Candidate

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate.

Disclaimer: The following article is for informational purposes only and does not constitute financial, medical, or professional advice. The content within this article is based on publicly available information and does not promote any specific products or companies. Readers are advised to perform their own research and consult with professionals where…